{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~4 mi. (Limoges, France, +144 more cities)
facility
Clinique Francois Chenieux ( Site 1209)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~4 mi. (Limoges, France, +93 more cities)
facility
CHU Limoges Hopital Dupuytren ( Site 0459)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
city
~4 mi. (Limoges, France, +67 more cities)
facility
CHU Limoges CHU Dupuytren ( Site 1011)
drug
carboplatin, +5 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~93 mi. (Poitiers, France, +145 more cities)
facility
CHU Poitiers ( Site 1109)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~93 mi. (Poitiers, France, +105 more cities)
facility
CHU Poitiers ( Site 0612)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions